NCT01151904

Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for chronic angle closure glaucoma.

Conditions

• Glaucoma, Angle-Closure

Interventions

Type	Name	Description
DRUG	brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution	COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
DRUG	latanoprost	Latanoprost administered in the affected eye(s) as prescribed by physician.

Timeline

• Start date: 2009-11-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2010-06-29
• Last updated: 2013-02-06
• Results posted: 2013-02-06

Locations

1 site across 1 country: Thailand